Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Ultrasonography of hepatocellular carcinoma: From diagnosis to prognosis

2.

Reversing the toxic relationship with high doses of chemotherapy in oncology.

3.

Screening for prostate cancer: is it time to give up digital rectal examination?

4.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment

5.

Prior authorizations draining time, energy from many cancer patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot